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P2Y purine nucleotide receptors (P2YRs) promote endothelial cell tubulogenesis through breast cancer cell-secreted nucleoside
diphosphate kinase (NDPK). We tested the hypothesis that activated P2Y1 receptors transactivate vascular endothelial growth factor
receptor (VEGFR-2) in angiogenic signaling. P2Y1R stimulation (10mM 2-methyl-thio-ATP (2MS-ATP)) of angiogenesis is suppressed
by the VEGFR-2 tyrosine kinase inhibitor, SU1498 (1mM). Phosphorylation of VEGFR-2 by 0.0262 or 2.62nM VEGF was comparable
with 0.01 or 10mM 2MS-ATP stimulation of the P2Y1R. 2MS-ATP, and VEGF stimulation increased tyrosine phosphorylation at
tyr1175. 2MS-ATP (0.1–10mM) also stimulated EC tubulogenesis in a dose-dependent manner. The addition of sub-maximal VEGF
(70pM) in the presence of increasing concentrations of 2MS-ATP yielded additive effects at 2MS-ATP concentrations o3mM,
whereas producing saturated and less than additive effects at X3mM. We propose that the VEGF receptor can be activated in the
absence of VEGF, and that the P2YR–VEGFR2 interaction and resulting signal transduction is a critical determinant of vascular
homoeostasis and tumour-mediated angiogenesis.
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The secretion of nucleoside diphosphate kinase (NDPK; EC 2.7.4.6)
orthologues by intracellular parasites (Gounaris et al, 2001; Chopra
et al, 2003), NDPK secretion by various carcinomas (Anzinger
et al, 2001; Okabe-Kado and Kasukabe, 2003), and NDPK’s
extracellular role in blood flow regulation (Buxton et al, 2001)
first lead us to propose a pathological role for secreted NDPK in
cancer and tumour angiogenesis. We have recently provided
evidence for a nucleotide-dependent regulation of angiogenesis by
breast cancer-secreted NDPK (Rumjahn et al, 2007). We observed
that extracellular NDPK by regeneration of extracellular nucleo-
tides can use endothelial P2 (Y) nucleotide receptors to stimulate
angiogenesis. Supporting our findings, the disruption of CD39
(ecto-apyrase EC 3.6.1.5) activity, the dominant vascular ecto-
nucleotidase and its regulation of nucleotide signaling, has been
observed to inhibit tumour angiogenesis and metastasis (Goepfert
et al, 2001; Jackson et al, 2007). The regulation of extracellular ATP
and ADP levels by ecto-apyrase is also known to play important
roles in cardiovascular physiology and pathophysiology
by activation of purinergic type-2 (P2) nucleotide receptors
(Erlinge and Burnstock, 2008).
P2 nucleotide receptors activated by ATP include both ligand-
gated ion channels (P2X) and heterotrimeric G protein-coupled
receptors (P2Y). P2Y receptors have become recognised as the
important regulators of carcinogenesis, endothelial regulation, and
blood flow regulation (Buxton et al, 2001; Burnstock, 2006; White
and Burnstock, 2006). Little is known about the role of P2Y
receptors (P2YRs) in angiogenesis with only a handful of reports
providing evidence supporting this notion. We have shown earlier
that P2YR signaling promotes angiogenic properties such as
endothelial cell tubulogenesis (Rumjahn et al, 2007), whereas
others have reported P2YR-mediated migration (Satterwhite et al,
1999; Kaczmarek et al, 2005) and permeability (Tanaka et al, 2004,
2006). Activated P2Y2 receptors can transactivate vascular
endothelial growth factor receptor-2 (VEGFR-2), suggesting a
direct link between extracellular nucleotides and established
tumour angiogenesis signaling (Seye et al, 2004). VEGFR-2
mediates the majority of the angiogenic and permeability-
enhancing effects of VEGF (Shibuya, 2006). Given this evidence,
we hypothesised that endothelial P2YR signaling interacts to
regulate VEGFR-2 signaling. Here, we provide evidence that P2Y1R
stimulation of human endothelial cells activates VEGFR-2
intracellular signaling to stimulate endothelial cell tubulogenesis,
a direct in vitro measure of angiogenesis. These data suggest that
tumour-mediated angiogenesis signaling may be, in part, mediated
by nucleotide receptor activation of the VEGFR-2 pathway and
may effectively lower the local requirement for VEGF.
MATERIALS AND METHODS
Cell culture
Human cardiac endothelial cells (HCECs) were earlier isolated by
Fluorescence Activated Cell Sorting for CD31 (PECAM) and
immortalised by human telomerase reverse transcriptase (hTRT).
Cloned human cord blood endothelial colony forming cells
(ECFCs) were purchased from Dynacell Life Sciences (Spring
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sHouse, PA, USA) and used experimentally between passages 6 and
13. The HCEC population represents an immortalised cell line,
whereas the ECFC population represents a primary cell line.
Human cardiac endothelial cells were grown in Dulbecco’s
Modified Eagle’s Medium (HyClone, Logan, UT, USA) supple-
mented with 10% foetal bovine serum ((FBS) Atlanta Biological,
Lawrenceville, GA, USA), penicillin–streptomycin (1500Ul
 1
–100mgl
 1), and 0.5mgl
 1 fungizone (Invitrogen, Carlsbad,
CA, USA). Human ECFCs were grown in endothelial growth
media-2 ((EGM-2) Clonetics, East Rutherford, NJ, USA) supple-
mented with 10% FBS (v/v), penicillin–streptomycin, and fungizone
as above. EGM-2 without angiogenic growth factors (EBM-2,
Clonetics) and with low serum (2% FBS) was used during
angiogenic experimental treatments. Cells were grown and main-
tained at 371C in a humidified atmosphere with 5% CO2/95% air.
In vitro angiogenesis scoring technique
A representative endothelial cell tubulogenesis (angiogenesis)
score for each condition was obtained by analysing digital images
( 100) collected from the central pointing corners of quadrants
I–IV in each culture well and averaging the four scores. As
described earlier (Rumjahn et al, 2007), an angiogenesis score (s)
represents the product of mean number of branch points (bp)
multiplied by mean pixel length (l) multiplied by mean pixel cell
surface area (a). Thus, s¼bp l  a.
Effect of disrupting VEGF signaling in P2Y
receptor-mediated angiogenesis
Human cardiac endothelial cells (3 10
4) on collagen-coated
plates were incubated for 24h with P2Y receptor agonists ATP
(P2Y1/2R; 100mM) and 2-methyl-thio-ATP (2MS-ATP) (P2Y1R;
10mM). EC tubulogenesis was also observed in the presence of 1mM
SU1498 (BIC50 of VEGFR-2 tyrosine kinase inhibitor (Strawn
et al, 1996); Sigma, St Louis, MO, USA) with either 100mM ATP or
10mM 2MS-ATP. EGM-2 was employed as a positive control,
whereas non-treatment controls were performed for normalisation
and comparison. EGM-2 stimulated growth was also observed in
the presence of 1mM SU1498 as a VEGFR-2 inhibition control. The
use of 10mM 2MS-ATP or 100mM ATP in promoting EC
tubulogenesis was maximal, consistent with known desensitisation
of P2Y1/2 receptors at higher agonist concentrations (Ralevic and
Burnstock, 1998; Rumjahn et al, 2007). SU1498 was chosen as it is
at least 100-fold more selective for VEGFR-2 kinase compared with
other receptor tyrosine kinases such as platelet-derived growth
factor receptor, epidermal growth factor (EGF) receptor, and
human epidermal growth factor receptor 2 (Strawn et al, 1996).
Endothelial colony forming cells (5 10
4) plated on growth
factor reduced (GFR) Matrigel (BD Biosciences, Bedford, MA,
USA) were incubated for 24h with varying concentrations (0.05–
10ng/ml; 1.31–262pM) of VEGF-A (VEGF; Sigma). Non-treatment
controls were performed for normalisation and comparison.
The experimentally determined maximal VEGF stimulation of
EC tubulogenesis (262pM) was used as a positive control in all
subsequent P2Y/VEGF experiments.
Endothelial colony forming cells (5 10
4) grown on GFR
Matrigel were incubated for 24h in the presence of 10mM 2MS-
ATP with or without 1mM SU1498. VEGF (262pM) in EBM-2 was
used as a positive control and was also used in the presence of 1mM
SU1498 to show the VEGFR-2-specific promotion of EC tubulo-
genesis. Non-treatment controls were performed for normalisation
and comparison.
Effect of P2Y1 receptor activation on VEGFR-2 activation
Endothelial colony forming cells were first grown to B75%
confleuncy on collagen-coated plates and then switched to EBM-2
supplemented with 0.5% FBS (v/v) overnight. ECFCs were next
stimulated with either VEGF (0.0262 or 2.62nM) or 2MS-ATP
(10nM or 10mM) for 10min. The cells were collected in cold NP-40
lysis buffer. This cell lysate was centrifuged at 10000g to remove
cellular debris.
Cell lysate supernatants (150mg) were incubated with KDR/
VEGFR-2 specific antibody (0.3mg rabbit IgG; Chemicon,
Rockford, IL, USA) and protein A/G agarose beads (20ml; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA). Proteins were
separated by electrophoresis on 10% polyacrylamide gels
(Bio-Rad, Hercules, CA, USA) and transferred to nitrocellulose
membranes. The membranes were then labeled for either overall
phosphotyrosines (1:1000 mouse IgG; Chemicon) or VEGFR-2
phosphotyrosine 1175 (1:500 rabbit IgG; Cell Signaling Techno-
logy, Danvers, MA, USA). Respective secondary antibodies
conjugated to either Alexa Fluor 680 or Alexa Fluor 800 fluorescent
dye (1:100000; Invitrogen) were used for detection. Antibody
incubations were carried out in 1:1 Odyssey blocking buffer (Licor
Biosciences, Lincoln, NE, USA) and PBS with 0.1% Tween-20 (v/v).
Bands were visualised using the Odyssey Infrared Imaging System
(V2.04). VEGFR-2 levels were checked for equal loading.
Effect of 2-Methyl-Thio-ATP signaling on angiogenesis
Endothelial colony forming cells (5 10
4) on GFR Matrigel-coated
plates were incubated for 24h with various concentrations of
2MS-ATP (0.1–10mM in half-log increments). VEGF (262pM) was
used as a positive control, whereas non-treatment controls were
performed for normalisation and comparison.
Effect of 2-Methyl-Thio-ATP and vascular endothelial
growth factor signaling on angiogenesis
Endothelial colony forming cells (5 10
4) on GFR Matrigel-coated
plates were incubated for 24h with various concentrations of
2MS-ATP (0.1–10mM in half-log increments) in the presence of
sub-maximal VEGF stimulation (ECFC tubulogenesis BEC50 as
experimentally determined; 70pM) in order to determine potential
co-activation between these angiogenic molecules. VEGF (262pM)
was used as a positive control, whereas non-treatment controls
provided normalisation and comparison.
Statistical analyses
All graphs were prepared using Prism Graphing Software (V5.01;
GraphPad Software, San Diego, CA, USA) and statistical analyses
were carried out using InStat Statistical Software (V3.06; GraphPad
Software), with Pp0.05 considered significant. Significance was
determined using non-parametric analysis of variance (Kruskal–
Wallis) with Dunn’s multiple comparisons post-test or non-
parametric t-test (Mann–Whitney). Data points and error bars
represent means±s.e.m. *Pp0.05; **Pp0.01; ***Pp0.001 (vs
negative control, unless otherwise indicated);
#Pp0.05 (2MS-ATP
alone vs 2MS-ATPþVEGF combination).
RESULTS
Endothelial P2Y1/2 receptors mediate in vitro angiogenesis
through VEGF signaling
As P2Y receptors have earlier been reported to interact with
VEGFR-2 (Seye et al, 2004), we investigated whether nucleotides
and VEGF-induced angiogenesis involved a common signaling
pathway. HCECs incubated with P2Y1/2 receptor agonists (100mM
ATP or 10mM 2MS-ATP) for 24h showed a B2.0-fold angiogenic
stimulation (Pp0.01; Figure 1A) that was suppressed back to
B1.3-fold control by 1mM SU1498. The BIC50 of SU1498, a
VEGFR-2 tyrosine kinase inhibitor, was used to limit non-specific
Nucleotide-dependent VEGFR-2 signaling
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sinhibition of other RTKs (e.g., platelet-derived growth factor
receptor and epidermal growth factor receptor) as reported earlier
with higher concentrations of this agent (Strawn et al, 1996). The
EGM-2 control produced a B2.5-fold increase over control
(Pp0.001; Figure 2), which, interestingly, was not affected by the
addition of 1mM SU1498. EGM-2 (a proprietary cocktail) includes a
mix of various angiogenic factors, including VEGF.
Using primary human endothelial cells, we also observed
that P2Y1 receptor activation stimulates VEGFR-2-mediated EC
tubulogenesis. ECFCs incubated with 10mM 2MS-ATP (P2Y1
receptor agonist) for 24h exhibited a B2.6-fold angiogenic
stimulation (Pp0.001; Figure 1B) that was suppressed back to
B1.9-fold control by 1mM SU1498. The VEGF control (262pM)
observed a B2.4-fold increase over control, which was suppressed
back to B1.5-fold control by 1mM SU1498. The SU1498 control
showed minimal angiogenic effect alone.
Activated endothelial P2Y1 receptors transphosphorylate
VEGFR-2
It is well known that ligand binding of a RTK (e.g., VEGFR-2)
induces dimerisation and subsequent activation of the receptor,
resulting in the autophosphorylation of tyrosine residues in its
cytoplasmic domain (Arora and Scholar, 2005). Knowing that
P2Y1R-mediated EC tubulogenesis uses VEGFR-2 intracellular
signaling, we further asked if P2Y1R activation by 2MS-ATP would
transphosphorylate (i.e., transactivate) VEGFR-2. ECFCs stimu-
lated with VEGF (0.0262 or 2.62nM) showed phosphorylation of
VEGFR-2 in a dose-dependent manner (Figure 1C; lanes 1 and 2),
consistent with the known activation of this receptor by its natural
ligand. ECFCs stimulated with 2MS-ATP (0.01 and 10mM) also
exhibited a similar dose-dependent phosphorylation of VEGFR-2
(Figure 1C; lanes 3 and 4). The non-stimulated (negative) control
showed a minimal level of basal VEGFR-2 tyrosine phosphory-
lation (Figure 1C; lane 5).
Phosphorylated tyrosine 1175 of VEGFR-2 is a binding
site for the SH2 domain of phospholipase C, which is an
important mediator of VEGFR-2-induced angiogenesis (Shibuya,
2006). We further observed that ECFCs stimulated with either
VEGF or 2MS-ATP phosphorylated VEGFR-2 Tyr1175 in a
similar dose-dependent fashion (Figure 1D and E). Human
umbilical vein endothelial cells also showed similar levels of
VEGFR-2 tyrosine phosphorylation by VEGF and 2MS-ATP (data
not shown).
Endothelial P2Y1 receptor activation stimulates EC
tubulogenesis in a dose-dependent manner
We observed that 2MS-ATP promotes a dose-dependent angio-
genic response with significant stimulation seen at higher
concentrations of X3mM 2MS-ATP, B2.5-fold increase over
control (Pp0.05; Figure 2A). We observed earlier that X10mM
2MS-ATP does not provide additional angiogenic stimulation
(Rumjahn et al, 2007), therefore an apparent tubulogenesis
EC50 would be B3mM. The VEGF control (262pM) stimulated
angiogenesis similar to that seen with 10mM 2MS-ATP.
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Figure 1 Endothelial P2Y receptor-mediated in vitro angiogenesis uses vascular endothelial growth factor (VEGF) signaling. Inhibition of VEGFR-2
intracellular signaling by SU1498 suppressed the pro-angiogenic potential of P2Y1/2 receptor agonists ATP and/or 2-methyl-thio-ATP (2MS-ATP) during a
24h EC tubulogenesis assay. (A) Control mean¼979.4±403.6 angiogenesis units. Negative control A; HCECs incubated in CDMEM supplemented with
2% FBS and 0.01% (v/v) DMSO. The angiogenic stimulation control used was endothelial growth media-2 (EGM-2). (B) Control mean¼817.4±31.1
angiogenesis units. Negative control B; ECFCs incubated in EBM-2 supplemented with 2% FBS and 0.01% (v/v) DMSO. The angiogenic stimulation control
used was EBM-2 containing VEGF, which was also suppressed by SU1498. (C–E); ECFCs treated with either VEGF (natural VEFGR-2 agonist) or 2MS-ATP
(P2Y1R agonist) for 10min observed respective phosphorylation and trans-phosphorylation of VEGFR-2. Samples were immunoprecipitated for VEGFR-2
and western blotted for (C) overall phosphotyrosines or (D) phosphotyrosine 1175. (E) Samples were directly western blotted for VEGFR-2 and
phosphotyrosine 1175. Negative control C and D; ECFCs incubated in EBM-2 supplemented with 0.5% FBS. Negative control E; EBM-2 with 1% FBS.
*Pp0.05; **Pp0.01; ***Pp0.001.
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sVEGF stimulates in vitro angiogenesis in a dose-dependent
manner
Endothelial colony forming cells incubated with varying concen-
trations of VEGF (0.00131–0.524nM) over 24h also exhibited a
dose-dependent increase in EC tubulogenesis with maximal
response at levels XB0.262nM (Figure 2B). On the basis of these
observations, an apparent VEGF EC50 of B70pM was used as a
sub-optimal level of VEGF stimulation of tubulogenesis.
2MS-ATP and VEGF use a common angiogenic pathway
To further investigate the notion of P2Y and VEGF cooperative
signaling, we incubated ECFCs with varying concentrations of
2MS-ATP (0.1–10mM) in the presence of constant tubulogenesis
EC50 concentration for VEGF (70pM). We observed that the
combination of sub-optimal levels of 2MS-ATP and VEGF do
indeed promote a significant dose-dependent angiogenic response
when compared with 2MS-ATP alone and control (Pp0.05;
Figure 2C). Lower concentrations of 2MS-ATP (o3mM)i n
combination with VEGF (70pM) exhibited additive-like angiogenic
stimulation, whereas higher concentrations (X3mM 2MS-ATP)
produced a more saturated and less than additive promotion of EC
tubulogenesis. VEGF at 70pM provided B51% of maximal VEGF
stimulated EC tubulogenesis (compared with 262pM), consistent
with our preliminary determination of the EC50.
DISCUSSION
We observed earlier that pathologically secreted NDPK stimulates
angiogenesis in a nucleotide-dependent manner principally
by P2Y1R (Rumjahn et al, 2007). Supporting this notion of
P2Y-mediated angiogenesis, it has been reported that endothelial
P2Y2R-mediated VEGFR-2 activation stimulates the expression of
pro-inflammatory vascular cell adhesion molecule 1 (VCAM-1)
(Seye et al, 2003, 2004). Inflammation and angiogenesis share
common mechanisms and are often seen concurrently, especially
in carcinogenesis. An appropriate example would be the use of
VCAM-1 in the recruitment of monocytes (undifferentiated
macrophages) and the differentiation of these cells into tumour-
associated macrophages, which can provide a microenvironment
conducive to tumour growth, metastasis, and of course angio-
genesis, as especially prevalent in breast and prostate cancers
(Pollard, 2004).
We suggest that P2YR-mediated VEGFR-2 activation can
promote tumour angiogenesis indirectly, as well as stimulate
direct angiogenic effects on the endothelial cells where the original
P2Y/VEGF signaling occurs. We investigated the latter notion and
observed the inhibition of ATP and 2MS-ATP-mediated EC
tubulogenesis by VEGFR-2 tyrosine kinase inhibitor SU1498.
This showed that VEGFR-2 intracellular signaling is a substantial
component of P2YR-mediated in vitro angiogenesis. The
unaffected angiogenic potential of EGM-2 (includes angiogenic
factors in addition to VEGF) by SU1498 is consistent with the
presence of multiple angiogenic pathways that can compensate for
impaired VEGF signaling. As this P2Y-mediated VEGFR-2 signal-
ing was observed in immortalised endothelial cells (HCECs), we
further showed that this signaling also exists in primary
endothelial cells (ECFCs). In the presence of a more relevant
VEGF angiogenic control, SU1498 (BIC50 tyrosine kinase activity)
produced a B60% reduction in stimulated EC tubulogenesis
indicating a tight association between VEGFR-2 tyrosine kinase
activity and our detection of EC tubulogenesis. VEGF (0.262nM)
exhibited maximal induction, whereas higher concentrations
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Figure 2 2-methyl-thio-ATP (2MS-ATP) and vascular endothelial growth factor (VEGF) cooperatively promote in vitro angiogenesis. P2Y1 or VEGF
signaling alone, as well as together stimulated EC tubulogenesis over a 24h duration. (A) ECFCs treated with varying amounts of 2MS-ATP produced a
dose-dependent stimulation of tubulogenesis. Control mean¼1292.8±65.1 angiogenesis units. Negative control A; ECFCs incubated in EBM-2
supplemented with 2% FBS. The angiogenic stimulation control used was EBM-2 containing VEGF. (B) VEGF (natural VEFGR-2 agonist) produced a dose-
dependent stimulation of tubulogenesis. Angiogenic responses varied between 1.25- and 3.00-fold control (defined as 0 and 100% stimulation). Negative
control B; ECFCs incubated in EBM-2 supplemented with 2% FBS. Curve trace was calculated using a non-linear fit of the data employing an equation
describing a sigmoidal curve. (C) ECFCs incubated with varying concentrations of 2MS-ATP combined with a constant sub-maximal level of VEGF (apparent
tubulogenesis EC50 of 70pM) produced additive stimulation of EC tubulogenesis only at lower concentrations of 2MS-ATP. Control mean¼655.7±81.8
angiogenesis units. Negative control C; ECFCs incubated in EBM-2 supplemented with 2% FBS. Fold control – 1.00 equals non-stimulated (negative) control.
(D) Hypothetical curve illustrating two molecules promoting a biological response (e.g., angiogenesis) via convergent signaling pathways, which limits the
potential of a larger response at higher concentrations. *Pp0.05; **Pp0.01; ***Pp0.001.
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s(41.31nM VEGF) exhibited signs of desensitisation, consistent
with known internalisation and degradation of activated VEGFR-2
(Ewan et al, 2006).
In addition to our functional angiogenesis data we observed that
P2Y1R activation by 2MS-ATP induces tyrosine phosphorylation,
general and tyrosine 1175-specific, on the cytoplasmic domain of
VEGFR-2 similar to that seen by its natural ligand VEGF. Tyr1175
of VEGFR-2 and its phosphorylation have been shown to be the
important regulators of VEGF-dependent angiogenic signaling
(Holmqvist et al, 2004; Sakurai et al, 2005; Shibuya, 2006). This
P2YR-mediated transphosphorylation and transactivation of
VEGFR-2 provides further evidence that P2YR uses VEGF
signaling to stimulate angiogenesis. This is the first report of
P2Y1R activation of VEGFR-2 angiogenic signaling.
P2Y1R activation of VEGFR-2 signaling was further investigated
by showing that varying levels of P2Y1R activation produces a
dose-dependent angiogenic response. When sub-maximal VEGF
signaling (experimentally determined EC50 of B70pM) was
subtracted from the combination of 2MS-ATP and VEGF, concen-
trations of 2MS-ATP X3mM observed angiogenesis levels less than
that seen from 2MS-ATP treatment alone (less than additive
effect). This can be conceptually explained when considering the
stimulation of a biological response (e.g., EC tubulogenesis) by two
molecules using the same signaling pathway, as illustrated in
Figure 2D. This dose-dependent saturation of VEGF angiogenic
signaling by 2MS-ATP further suggests that P2Y1R-mediated
angiogenesis is dependent on VEGFR-2 signaling and moreover,
that VEGFR-2 does not need its natural ligand to become activated.
P2Y receptors may additionally use their own separate signaling
pathways independent of VEGFR-2 to promote angiogenesis, and
it is possible that these independent pathways converge at one or
more distal effectors.
We now further expand our original hypothesis to include
VEGFR-2 signaling as a significant contributor to P2YR-induced
angiogenesis, which cancer cells can exploit to pathological
advantage by secretion of NDPK (Figure 3). Our demonstration
of productive interaction between P2Y and VEGF signaling
predicts that low levels of ATP and VEGF can cooperate to
stimulate considerable angiogenesis. Dynamic regulation of these
two molecules (ATP4VEGF or VEGF4ATP) may be used to
produce similar angiogenic responses in a temporal- and
environment-dependent manner. With respect to pathological
angiogenesis, tumour vasculature is more sensitive to VEGF
withdrawal as it mimics immature vessels that are extremely
dependent on VEGF signaling (Benjamin et al, 1999). Thus we
propose that dual inhibition of P2YR and VEGFR-2 signaling may
provide an effective mode of combinational anti-angiogenic
therapy. It is interesting that, this P2YR activation of VEGFR-2
intracellular signaling may also, in part, explain constitutive
VEGFR-2 activation in the absence of exogenous VEGF (Lee et al,
2007). Therefore, P2YR-VEGFR2 signaling may be important in
describing and understanding VEGF signaling required for endo-
thelial homoeostasis in both tumour as well as normal vasculature.
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